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1. Introduction 
Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglicemia 
resulting from peripheral resistance to insulin, reduction of pancreatic secretion of such 
substance and increase of glycosis hepatic production, causing, after a long time, a series of 
complications (1). 
Clinical diabetes complications may affect the great and medium arteries - causing coronary 
artery disease and peripheral artery disease - or the little arteries, causing diabetic 
microangiopathy – retinopathy, nephropathy and neuropathy (2,3). 
2. Pathophisiology 
Elevated glycemia induces a series of bichemical and cellular abnormalities which may 
cause vascular alterations found in diabetic retinopathy (4,5,6). Mechanisms induced by 
hyperglycemia  which can cause endothelial cells dysfunction include increase of polyol 
pathway flux, accelerated and non-enzimatic formation of advanced glycation end-products 
(AGES), increase in diacylglycerol formation (with consequent activation of protein kinase C 
– PKC), increase of hexosamine pathway flux and a disturbed oxi-reduction status (4,5,6,7). 
All these mechanisms may contribute to the known phisiological characteristics of diabetic 
complications through increase of cytokines and growing factors regulation, and through 
formation of oxygen and nitrogen derived free radicals (8).   
2.1 Free radicals 
A free radical can be defined as a chemical species that has a non-paired electron (9). It may 
be also considered as a fragment of a molecule (10). Thus, free radicals can be formed in 
three ways: 
 By cliving a covalent link of a normal molecule, with each of the fragments retainning 
one of the paired electrons (10); 
 When a normal molecule lose one electron (10) and 
 When a normal molecule receives one electron (10).  
The most relevant free radicals in biological systems are those derived from oxygen 
(9,10,11). 
www.intechopen.com
 
Diabetic Retinopathy 
 
54
3. Oxidative stress 
It is said that a cell suffers oxidative stress when formation of free radicals overcomes 
hability of cellular antioxidant system (12). That may happen when a lot of free radicals is 
formed, when endogenous antioxidant defenses are diminished or, more commonly, when 
both events occur (12). Excessive free radical production may damage any cellular structure, 
including membrane (lipid peroxidation), proteins (anomalous polimerization) and nucleus 
(desoxirribonucleic acid – DNA - lesion) (12). 
In diabetes, free radical formation, together with antioxidant deficiency, increases with time 
and may have an important role in retinopathy development (13,14). 
Retina is known as an important target of diabete mellitus (1). Because of its high oxygen 
requirement and due to its unsaturated lipid content, retina may be a selective site for free 
radical production and for lipid peroxidation (1). 
In endothelial cells, intracellular hyperglycemia promotes an increase in superoxide radical 
production at mitochondrial level (10). It is thought that such increase of superoxide 
production is the activator process of all pathways enrolled in diabetic complications 
pathogenesis (10). It is also seen an increase in nitric oxide production (NO) that is 
particularly damaging because it reacts with oxygen and produces peroxynitrite, a powerful 
oxidant (10). Peroxynitrite is cytotoxic because it inhibits mitochondrial transportation of 
electrons, oxidizes sulphidril groups in proteins, begins lipid peroxidation without the 
necessity of transition metals and nitrates aminoacids (such as tyrosine), what affects many 
signal transduction pathways (10). Chronic hyperglycemia promotes non-enzimatic 
glycation of proteins and glycated proteins may increase oxidant generation by activating 
fagocytes or by releasing superoxide and hydrogen peroxyde directly (10). Besides, AGEs 
estimulate oxidant production through specific interactions with receptors that are present 
in vascular cells (10). 
4. Alterations of blood flux regulation 
Endothelins are the main endothelial vasoconstrictors (12). In endothelial cells of retinal 
vessels, main endothelin is the subtype ET-1, that is synthethized and released by the action 
of several factors (growth factors, cytokines and insulin, among others) and is negativelly 
controlled by prostaciclin, nitric oxide and heparin, among other substances (12). ET-1 
interacts with specific membrane receptors that are present in vascular smooth muscle fibers 
(ETA and ETB) and it triggers a vasoconstrictor effect (12). In diabetic animals retina, 
synthesis and activity of ET-1 and ET-3 are increased and factors which inhibit such actions 
are decreased; thus, endothelins are considered one of the factors that contribute to a 
reduction of retinal blood flux and to endothelial capillary proliferation (12). 
Among the vasodilating factors those which deserve a greater attention are prostaciclin and 
nitric oxide (12). Prostaciclin is formed from arachidonic acid through participation of 
cycloxigenase, to form ciclic endoperoxides, as it occurs in platelets (12). Main difference 
between prostaciclin synthesis in platelets and in endothelium is that the first involves 
thomboxane synthetase that produces thromboxane A2 (TxA2, a powerful vasoconstrictor 
and platelet agregant) while the last one involves prostaciclin synthetase (a powerful 
vasodilating and platelet disagregant) (12). Due to shared biochemical origin but opposed 
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effects of both prostanoids, it is accepted that a proper balance between platelet 
thromboxane and vascular prostaciclin be fundamental to physiological interaction between 
platelets and vessel walls (12). 
5. Vascular nitric oxide defficiency origin in diabete 
In diabete, hyperglycemia may actvate PKC isoform bII in endothelial cells, what reduces 
calcium ingress in cells and, consequently, nitric oxide synthesis (15). Besides, PKC 
promotes superoxide generation in endothelial cells and it quenches in a reaction that 
produces the toxic radical peroxynitrite (15). This way, overactivation of PKC mediated by 
hyperglycemia may reduce the synthesis or accelerate the loss of nitric oxide (15). 
Hyperglycemia also provides a substrate increase for endothelial aldose reductase (15). Such 
enzyme generates sorbitol from glucose in a reaction that oxidizes NADPH – and, this way, 
decreases disponibility of reducing co-factor for NO sintase (16). 
Glycated tissue proteins (whose levels increase as a consequence of hyperglycemia) may 
generate superoxide in a non-enzymatic reaction that needs transition metal catalysis; such 
factor also contributes to NO deficiency associated to hyperglycemia (15). Besides, AGEs 
may also extinguish NO directly (15). 
6. Pathogenic implications of NO deficiency 
Vascular deficiency of NO may be critical for pathogenesis of micro and macrovascular 
complications of non-controlled diabetes mellitus (15). This may be appreciated in the light 
of physiological importance of basal activity of NO in maintaining an appropriate arteriolar 
vasodilation, stabilizing platelets and preventing excessive activation and circulating 
leucocyte adhesion (15). Loss of such activity may clearly promote ischaemia by inducing 
arteriolar vasoconstriction and microvascular occlusion by activated adhering leucocytes 
and thrombosis (15). Besides, NO increases sodium-potassium pump activity in arterial wall 
and in axons of peripheral nerve (15). Reduction of sodium-potassium pump activity in 
endothelial capillary cells exposed to hyperglycemia could, in the same way, be attributed to 
a lesser production of NO (15). 
In diabetes, vasoconstrictor impact of NO deficiency is exacerbated by stimilus of PKC over 
endothelin production (15). There is also evidence that endothelial synthesis of PGI 1 
(prostaciclin) tends to be subnormal in diabetics (15). Once prostaciclin, as well as 
protaglandin E1 (PGE1), present many physiological effects that are complementary to those 
of NO – including vasodilation – it is probable that an impairment in its production 
amplifies the pathogenic impact of NO deficiency (15). 
In diabetes, NO deficiency and excessive activation of endothelial PKC cause an increased 
synthesis of Platelet Activating Factor (PAF) (15). Endothelial PAF, confined to luminal 
endothelial membrane, stimulates receptors in marginated leucocytes that circulate along 
post-capillary venules, inducing activation of these leucocytes and taking them to express 
ǃ2-integrins (15). Such phenomenon possibilitates leucocytes to adhere tightly to endothelial 
surface (15). One of the main endothelial targets to which such endothelins adhere – ICAM-1 
– is also estimulated by PKC activity (15). 
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Activated leucocytes also synthethize leucotrien B4 (LTB4), what also increases PKC activity 
more yet by estimulating phospholipase C-b (15). 
Leucocytes are greater and more viscous than erithrocytes and the activation process 
increases their polymerization because of its action over actin (15). Thus, under conditions in 
which pressure gradient through capillaries is reduced – as in vascular beds supplied by 
estenotic arteries or in constricted arterioles – activated leucocytes become edged in 
capillaries, preventing vascular flux (15). 
In diabetics, blood viscosity increases due to greater fibrinogen plasmatic levels and it may 
damage microcirculatory flux more yet (15). This way, these factors promote retinal 
hypoxia, which causes angiogenic factors release – more notably, vascular endothelial 
growth factors – which induce neovascularization (15). 
7. Alterations of control mechanisms of growth factors 
Among all growth factors, VEGF is the innermost factor related to retinal neovascularization 
because it takes part in formation of new vessels which appear after retinal ischaemia (12). 
VEGF is member of a great family of proteins with angiogenic and mitogenic capabilities 
(12). It is produced in retina in pigmented epitelium, in neurosensorial retina, in pericytes 
and in vascular smooth muscle layer (12). Even in the earliest stages of retinopathy (early or 
backgraund retinopathy) it is already observed an increased expression of (VEGF) 
messenger ribonucleic acid (mRNA) in retinal pigmented epitelium (12). 
Studies about induction of permeability in retinal endothelial cells in culture showed that 
VEGF induces transitory and transcellular hyperpermeability, which involves nitric oxide 
synthase activation and nitric oxide formation (17). It is believed that such phase is followed 
by a sustained increase of paracellular permeability due to a reduction of ocludin protein of 
tight junctions and it involves urokinase receptor expression (uPAR), what may deflagrate 
plasmin formation and matrix metaproteinase activation (17). 
VEGF, in turn, still promotes ICAM-1 expression by endothelial cell, what causes leucocyte 
activation and cytokine release leading to an amplification of inflammatory response (12,18). 
8. Pigmented Epitelium Derived Factor (PEDF) 
Besides causing vascular lesion, diabetes also presents an adverse and early impact over 
neural retina (2,12,18). Studies with diabetic patients showed early alterations in visual 
function, including damage of colored vision and contrast sensibility, and reduction of 
electroretinogram oscilatory potentials (2,12,18). Such alterations frequently precede 
microvascular lesions establishment and predict retinopathy worsening in a better way than 
clinical characteristics, suggesting that neurodegeneration, as well as vascular dysfunction, 
be an important characteristic of diabetic retinopathy (2,12,18). It was suggested that 
metabolic factors that cause such phenomenon include loss of trophic support mediated by 
insulin or a lesion due to excessive accumulation of hexosamine, ǂ-Tumoral Necrosis Factor 
or glutamate (2,12,18). Data that show reduced levels of Pigmented Epitelium Derived 
Factor (PEDF) in ocular fluids and vitrectomy species of patients with diabetic retinopathy 
suggest that loss of PEDF contributes to neuroglial cells toxicity induced by diabetes 
(2,12,18). 
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PEDF occurs naturally in eye and it is expressed in multiple retinal cells, including retinal 
pigmented epithelial cells, glial cells, vascular endothelial cells and neurons (17). It was 
demonstrated that treatment with PEDF prevents retinal neovascularization in a model of 
ischaemic retinopathy (17). Recently it was verified that PEDF blocks the increase in 
vascular retinal permeability induced by ocular injections of VEGF (17). PEDF may also 
function as an antioxidant once it supresses reactive species generation mediated by 
NAD(P)H oxidase and blocks increase of expression of VEGF induced by oxidative stress 
(17). Studies of ocular fluids of patients with active neovascularization show an inverse 
correlation between VEGF levels (increased) and PEDF ones (decreased), suggesting that a 
change in balance between PEDF and VEGF levels may contribute to development of retinal 
neovascular disease (17). 
Reductions of mRNA PEDF levels were related in endothelial cells in culture and in 
pericytes exposed to oxidative stress conditions, as well as in endothelial cells treated with 
TNF-ǂ (17). Studies with cells in culture indicate that hypoxia and VEGF inhibit PEDF levels 
by increasing matrix metalloproteinases that degrade and inactivate PEDF (17). 
9. Poly (ADP-ribose) polymerase and diabetic vascular disfunction 
Poly(ADP-ribose)polymerase (PARP), also known as poly(ADP-ribose)synthase (PARS), is a 
nuclear enzyme abundant in eukaryotic cells that takes part in DNA repair in answer to 
genotoxic stress (19). 
Compulsory trigger to PARP activation is DNA breakdown, which can be induced by a 
variety of environmental stimulations and free / oxidizing radicals, more notably hydroxil 
and peroxynitrite radicals (8,20). 
When activated by DNA breakdown, PARP begins a cicle that consumes energy by 
transfering ADP ribose units from NAD+ to nuclear proteins (8,19). Such process results in a 
rapid depletion of intracellular supplies of NAD+ and ATP, reducing glycolisis tax (and 
mitochondrial respiration), as well as NADP levels (a co-factor for pentose way and of bio-
reducing synthetic ways, involved in maintaning reduced glutatione pools), causing cellular 
dysfunction and death (8,19). It was showed that PARP activation occurs in a great variety 
of pathological states, including reperfusion lesion of colon, kidney, skeletal muscle and 
myocardium, inflammatory diseases such as colitis, diabetes and arthritis, septic and 
haemorragic shocks (8,19). It was demonstrated that PARP activation has also a central role 
in cardiovascular diseases, including encephalic vascular accident (EVA), atherosclerosis, 
cardiac ischaemic disease, doxorrubicin toxicity and diabetic cardiovascular disfunction (8). 
PARP activation in answer to elevated glucose levels can be attenuated by SOD (8). 
PARP activation may be relevant in endothelial cells dysfunction induced by hyperglycemia 
(8). Endothelial cells exposed to hyperglycemia during 1-2 days present an intense 
suppression of high energy phosphate cell levels, as well as NAD+ and NADPH levels (8). 
Since constitutive NO-sintetase (ec-NOS) is a NADPH-dependent enzyme, it is conceivable 
that NADPH cellular depletion in cells exposed to hyperglycemia be directly responsible for 
ec-NOS activity suppression and for reduction of endothelium dependent relaxing capacity 
of diabetic vessels (8). In diabetic patients, hyperglycemia effects over NADPH levels may 
be exacerbated by aldose redutase increased activity, which also depletes NADPH as well as 
generates reactive oxidants (8). 
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PARP activation in endothelial cells exposed to hyperglycemia may be a common factor 
among three of major hypotheses by which hyperglycemia causes diabetic complications: 
activation of PKC isoforms, increased flux of hesosamine pathway and AGEs increased 
formation (8,21). Each of these pathways may be activated by superoxide overproduction 
from mitochondrial electron transport chain and it is induced by hyperglycemia (8,21). 
Superoxide overproduction in endothelial cells exposed to hyperglycemia results from 
inhibition of activity of glyceraldeid-3-phosphate dehydrogense (GAPDH) enzyme, being 
PARP the mediator of such effect (8). Inhibition of GAPDH activity also activates pro-
inflammatory transcription factor NF-κǃ that is PKC-dependent in endothelial cells (8). 
Inhibition of GAPDH activity is a result of poly(ADP-ribosyl)ation of enzyme by PARP and 
can be reversed by inhibiting PARP (8). GAPDH is a multifunctional enzyme that presents 
effects as much in cytoplasm as in nucleus and it has been implicated not only in normal 
physiology (exportation of nuclear RNA, DNA replication, DNA repair, exocitotoxic 
membrane fusion, cytoskeletal organization and phosphotransferase activity), but also in 
pathological states, such as, neurodegenerative diseases (Parkinson’s disease), cancer 
(prostate) and in viral pathogenesis, where it was demonstrated that GAPDH presents a role 
in apoptotic cellular death (8). It has been demonstrated that GAPDH is the link between 
PARP activation and endothelial cells diabetic dysfunction (8). 
10. Vitamin C 
10.1 Introduction 
Vitamin C (ascorbic acid) is an essential micronutrient for normal body metabolism and it is 
present in fresh fruits, particularly in citrus ones, and in vegetables (15). Its deficiency causes 
scurvy (22). 
Minimum necessary requirement of vitamin C is 60 mg/day for health and non-smoker 
people (22). 
Vitamin C is a co-factor of several enzymes: 
1. Pro-collagen-proline dehidrogenase (proline dehidrogenase) and procollagen lisine 5-
dehidrogenase (lysine desidrogenase), involved in pro-collagen synthesis (22). Thus, 
vitamin C deficiency causes teeth losses, joint pains, bone and conective tissues 
disorders, and a deficient wound scar, all of which are characteristics of scurvy (22); 
2. Deoxigenases, involved in carnitine biosynthesis, essential substance for long chain fat 
acids transportation to the interior of mitochondria (22). Thus, vitamin C deficiency 
results in fatigue and letargy, initial symptoms of scurvy (22); 
3. Dopamine-monoxigenase, that catalyses conversion of dopamine into norepinephrine 
(22). Thus, norepinephrine deficiency must be related with depression, hipochondria 
and humor alterations that occur in scurvy (22). 
Vitamin C was also implicated in cholesterol and biliary acids metabolism, through 
cholesterol 7ǂ-monoxigense, and in adrenal steroid metabolism (22). 
Other acitivties of vitamin C include thiol enzymes maintenance in a reduced state, and a 
saving effect of glutatione (an important intracellular antioxidant) and tetrahidrofolate (co-
factor for cathecolamine synthesis) (22). 
www.intechopen.com
 
Diabetic Retinopathy 
 
59 
10.2 Antioxidant effect 
According to the Panel on Dietary Antioxidants and Related Compounds of the Food and 
Nutrition Board, an antioxidant may be defined as a substance that reduces significantly the 
adverse effects of free radicals over normal physiological function (22). 
Vitamin C (or L-ascorbic acid) is called electron donnor antioxidant due to its hability to 
prevent oxidation of other compounds by linking to their electrons (23). While ascorbic acid 
is oxidized in a stable and non-reactive form, free radicals are reduced to water and do not 
cause cellular lesion any longer (23). 
Vitamin C scavenges superoxide and hydroperoxyl, watery peroxyl, oxygen singlet, ozone, 
peroxynitrite and nitrogen dioxide, nitroxide radicals and hypoclorous acid, protecting, this 
way, other substrates from oxidative lesion (16,22). 
Besides, vitamin C regenerates ǂ-tocopherol (vitamin E) from ǂ-tocopheril radical (22). That 
is particularly important because ǂ-tocopherol may act as a pro-oxidant in absence of co-
oxidants like vitamin C (22). 
10.3 Effects over coagulation, platelets and vessels 
Studies showed an inverse association between vitamin C plasmatic concentrations and 
coagulation factors (22,24). 
10.4 Effects over platelets 
In vitro studies showed that physiological concentrations of vitamin C may increase PGE1 
and PGI1 production, resulting in a reduction of platelet aggregation and thrombus 
formation (22). Besides, low concentrations of vitamin C are also associated to greater levels 
of Plasminogen Activating Inhibitor 1, a protein that inhibits fibrinolysis (22). 
10.5 Vitamin C and nitric oxide 
Other studies demonstrated that vitamin C restores endothelium depending vasodilation in 
diabetic type 1 patients and in acute hyperglycemia in health humans, while studies realized 
with type 2 diabetics showed varied results (24). Several mechanisms may be responsible for 
such effects and, probably, they are related to vitamin C antioxidant activity (22). 
NO presents an important  role in vasodilation and it also inhibits platelet aggregation and 
lecocyte adhesion (22). Studies showed that NO concentrations are reduced through its 
reaction with superoxide radicals and because of its release by oxidized LDL (22). This way, 
vitamin C may prevent NO breakdown by scavenging superoxide radicals or by preventing 
oxidized LDL formation (16,22,23). 
10.6 Effects over capillary fragility 
Vitamin C deficiency promotes the following alterations over vascular tissues: inner and 
basal membrane thickening, extra-cellular matrix accumulation due to a reduced sulfatation, 
endothelium tight junctions loss (with consequent increase of transcapilar escape tax – TET) 
and capillary fragility (24). Such findings are also met in diabetic microangiopathy (24). 
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10.7 Effects over diabetic complications 
A recent report showed that all alterations induced by hyperglycemia – including aldose 
redutase, PKC and AGEs increases – are reversed by inhibiting free radicals production 
induced by glucose (25). Such fact gives the possibility that, by blocking glucose induced 
oxidative stress, it may also be possible to prevent lesions caused by other pathways (25).    
Vitamin C presents a central role in antioxidant defense system and may help to mitigate 
oxidative stress associated to diabetic complications (22). In fact, there are reports that high 
dose vitamin C diets are associated to reversion of early signs of retinopathy and to 
normalization of capillary resistance in diabetes mellitus, confirming its antioxidant 
protector role in blood vessels lesion (9,26). 
10.8 Intracellular transportantion of vitamin C 
It is known the existence of two distict mechanisms of vitamin C transportation into the cells 
(25): 
1. A sodium-dependent mechanism that is mediated by a pair of ascorbate carriers, which 
is predominant in hemato-encephalic barrier, osteoblasts, muscles, placenta, intestine 
walls, brush border kidney cells, liver, brain and in the majority of endocrine and 
neuroendocrine systems, and it is not affected by glucose plasmatic levels (25); 
2. An extremely sensible mechanism to glucose blood levels and dependent of some 
members of glucose transporters family (GLUT) (25). 
There are also some cellular types, as linfocytes and red blood cells, that use both ascorbate 
captation mechanisms (25). 
Once dehidroascorbate (DHA) enters cells, it is converted into ascorbic acid and stored (25). 
Glucose and DHA co-transportation by GLUT’s in certain cellular types suggests a new 
causative mechanism of disease in these particular cellular types (25). Studies show an 
increase in free radicals production  induced by hyperglycemia in target-organs affected by 
diabetes mellitus (25). Thus, it is suggested that free radicals production is the main 
causative pathway of diabetic complications (25). 
Ascorbic acid functions as an important component of cellular defense against oxygen 
toxicity and lipid peroxidation caused by free radicals (13,26). Reduced ascorbic acid levels 
have been observed in diabetic patients, mainly in those with microangiopathy (13,26). 
Ascorbic acid caption by cell is mediated by a process related to glucose transportation and 
it was demonstrated that a high glucose extracellular concentration in diabetics may damage 
such caption and accentuate problems related to deficiency of such vitamin (13,26). 
That phenomenon would deprive cells of central antioidant and could cause accumulation 
of free radicals followed by activation of PKC and aldose redutase pathways and by AGEs 
production in diabetes (25). 
Such effects are limited to certain specific cellular types that depend on glucose and DHA 
co-transportation by GLUT (25). 
Since DHA and glucose compete for GLUT carriers, each of them can inhibit transportation 
of the other (25,26). Basal blood glucose in non-controlled diabetes is tipycally elevated and, 
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during hiperglycemic episodes, it increases still more (25,26). Besides, ascorbate levels tend to 
be significantly reduced in non-controlled diabetes, even in diabetics who eat diets rich in such 
substance (25,26). It seems that ascorbate loss is due to its excretion (together with glucose) by 
the kidneys, to a blockade of its recaption due to a greater glucose concentration and to its 
reduced absorption by kidney tubules (due to osmotic diuresis and glucosuria) (25). 
It is verified, in average, a reduction between 30 and 80% of normal taxes of entrance of 
DHA into cells (25). Thus, DHA transportation into nerves, retina, kidney and other tissues 
that are unique or mainly GLUT –dependent, will be intense and chronically reduced (25). 
This way, it is probable that hyperglycemia results in a vitamin C deficiency in certain types 
of cells (such as peripheral neurons, pigmented cells and retinal vascular endothelial cells) 
which depend mainly or exclusively on GLUT carriers for vitamin C caption (25). 
11. Preventing and treating diabetic complications 
Thus, it is believed that ascorbic acid may prevent or even treat complications associated to 
diabetes by affecting proteic glycosilation (25,27), sensibility to insulin, retinal blood flux 
and oxidative stress (25,28). 
11.1 Adverse effects of vitamin C 
Adverse effects from excess of vitamin C are hemochromatosis or iron overload, an increase 
of uric acid and oxalate excretion (with consequent development of kidney stones), nausea, 
vomiting and diarrhea (29). 
12. Superoxide dismutase 
12.1 Physiopathology of diabetes chronic complications 
According to what has already been said, diabetes chronic complications occur as a 
consequence of persistent hyperglycemia (7). Hyperglycemia, in turn, promotes glucose 
auto-oxidation, AGEs formation and its interaction with RAGEs, activation of several 
isoformes of PKC, induction of poliol pathway and an increase of flux of hexosamine 
pathway (7). 
Recently, it was made a hypothesis according to which all these processes would be a 
consequence of an increase of superoxide production by respiratory mitochondrial chain 
during hyperglycemia (7,30). 
Mitochondrial role in retinopathy pathogenesis is supported by reports which show that 
retinal mitochondria presents a dysfunction in diabetes (30,31). Eight-month diabetic rats (a 
duration in which capillary cell apoptosis is seen in retina) present an increase of citocrome c 
release in citosol and of Bax pro-apoptotic protein in mitochondria (30,31). Besides, 
incubation of retinal capillary cells in a hyperglycemic environment results in these precise 
abnormalities, which are accompanied by increased cellular apoptosis (30). 
Retinal capillary cells apoptosis is an early event in diabetic retinopathy pathogenesis, and 
oxidative stress is linked to accelerated apoptosis of retinal capillary cells (30). Because it 
was demonstrated that retinal capillary cells are lost through apoptosis before other 
hystopathological alteration is detectable and because treatments that inhibit retinopathy 
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development also inhibit apoptosis and caspase-3 activation, it is suggested that superoxide 
presents an important role in diabetic retinopathy pathogenesis (30). 
This way, reduction in superoxide production by mitochondria or an increase in its tax of 
decomposition by antioxidants could block many of hyperglycemia pathological 
consequences (7). 
13. SOD history 
In 1938, Mann and Keilin described a blue-greened protein containing copper 
(hemocupprein), which they have isolated from ox blood (9,32). In 1953, a similar protein 
was isolated from horses’ liver and it was called hepatocuprein (9). 
In 1969, McCord and Fridovich related that an erithrocitic protein was capable of removing 
catalitically superoxide radical, that is, it functioned as a superoxide dismutase enzyme 
(SOD) (9,33). Posteriorly, it was demonstrated that SOD is identical to human erithrocuprein 
and to bovine hemocupprein described previously (31,33). 
Soon, SODs were isolated from a variety of eucharyotes and prokaryotes (33). All 
eucharyotic SODs had copper and zinc (CuZnSOD), while procharyotic ones had 
manganese (MnSOD) (33). While he worked with chicken livers, Fridovich perceived that it 
contained two types of SOD, one localized in mitochondria and another one localized in 
cytosol (33). Surprisingly, mitochondrial SOD had manganese (33). 
Similarity between mitochondrial and bacterial SODs suggests that mitochondria has 
evolved from an endocellular symbiotic relation with procharyotes (33). 
Together with Fred Yost, Fridovich also isolated a SOD which contains iron (33).  
Howard M. Steinman and cols. determined the complete sequence of aminoacids of 
CuZnSOD (33). Steinman and Robert L. Hill determined the sequence of the first 29 residues 
of ending amino of mitochondrial Mn dismutase, of bacterial Manganese dismutase and of 
bacterial Iron dismutase (33). Elevated degree of similarity of identity between bacterial and 
mitochondrial dismutases gave an additional support to endosymbiotic origin of 
mitochondria (33). 
13.1 SOD actions 
SOD constitutes primary defense against superoxide radicals and its reaction with such free 
radicals results in hydrogen peroxide formation (16). 
Due to its mitochondrial localization, MnSOD is considered the first line of defense against 
oxidative stress (30). 
It was demonstrated that there is less mitochondrial SOD activity in retina during capillary 
cells apoptosis and during the appearance of diabetic retinopathy hystopathological 
characteristics (30). 
In vivo and in vitro studies suggest that MnSOD presents a protecting role against 
development of diabetic retinopathy because an increase in its expression in isolated retinal 
endothelial cells protects retinal capillary cells from oxidative stress induced by glucose and 
from capillary cells apoptosis (30). 
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13.2 Effect of MnSOD over “hiperglycemic memory” 
A paradox in diabetes is called “hiperglycemic memory” and refers to a persistent 
progression of microvascular alterations induced by hyperglycemia during subsequent 
periods of normal glycemic homeostasis (34). That outstanding phenomenon occurred in 
eyes of diabetic dogs during a post-hyperglycemic period of euglycemia (34). Eyes were 
hystologically normal during 2,5 years before exposition to elevated and sustained glycemia 
(34). But, after a subsequent period of 2,5 years of normal glycemia, eyes developed severe 
retinopathy (34). Worsening of retinopathy, in spite of sustained normoglycemia, was also 
related in rats with streptozocin induced diabetes implicating that an isolated good glycemic 
control does not stop diabetic microangiopathy progression in its late stage (34). 
Results from Epidemiology of Diabetes Interventions and Complications Study indicate that 
hiperglycemic memory also occurs in human patients (34). It was demonstrated that the 
effects of conventional and intensive treatments over occurrence and severity of post-study 
diabetic retinopathy and nephropathy persist until 4 years after Diabetes Control and 
Complications Trial, in spite of almost identical glycosilated hemoglobin values during the 
4-year follow-up period (34). It is interesting that obtaining normoglycemia through 
pancreatic transplantation is not effective yet in reducing diabetic retinopathy progression 
(34). Other studies demonstrate that previous glycemic exposure and glycemic level at first 
visit also have influence over diabetic retinopathy development (34). The lesson from those 
studies is that achieving the best glycemic control when diabetes is diagnosed seems to be of 
outstanding importance once HbA1c levels already during the first year of disease are 
related to posterior development of diabetic retinopathy (34). 
As it was suggested by Brownlee and cols., superoxide mitochondrial production induced 
by hyperglycemia (oxidative stress) may provide an explanation for development of 
complications during post-hyperglycemia normal glycemia periods (30,34). 
Treatments that inhibit activation of apoptosis promoting enzyme and, consequently, 
diabetic retinopathy development, reduce oxidative stress in retina (30). Thus, it was 
observed that increases in MnSOD expression prevents oxidative stress induced by glucose 
in retinal endothelial cells (30). This way, MnSOD could be used in treatment of 
“hiperglycemic memory”. 
14. Adverse effects 
Superoxide dismutase does not present known adverse effects (9). 
15. Conclusion 
There are evidences of a key-role of free radicals in diabetic retinopathy pathogenesis. 
Retina is rich in polyunsaturated fat acids and presents glucose oxidation and oxygen 
caption taxes greater than any other tissue, being, this way, extremely susceptible to 
increased oxidative stress. Alterations of enzyme activity of antioxidant system (such as 
superoxide dismutase) seem to be one of the possible sources of oxidative stress in diabetes. 
Recent evidences also point to a participation of oxygen reactive species in mithogenic 
cascade began by tyrosine kinase receptors of several growth factors, including Vascular 
Endothelial Growth Factor (VEGF). Antioxidants, at least, inhibit some metabolic 
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abnormalities and pathological alterations induced by hyperglycemia. Therefore, it is 
reasonable to postulate that an antioxidant treatment may be useful to prevent diabetic 
retinopathy progression and that medication combinations could be necessary to prevent 
visual loss in diabetic patients. Ascorbic acid is present in great amounts in human eyes and 
its hability of scavenging oxygen reactive species may have importance in the treatment of 
diabetic retinopathy. Biological role of superoxide dimutase is scavenging superoxide, 
which is generated in vivo after exposition to oxygen. Retinal Pigmented Epithelium (RPE) 
has elevated levels of Manganese-Superoxide Dismutase and a reduction of its levels may be 
related to retinal lesion. Antioxidants, such as vitamin C and superoxide dismutase, may 
provide aditional beneficial effects to patients with diabetic retinopathy. Thus, vitamin C 
and superoxide dismutase present the potential of influencing positively ocular disease.      
16. References 
[1] Yildrim Z, Ucgun NI, Kilic N, Gursel E, Sepici-Dincel A, et al. Antioxidant enzymes and 
diabetic retinopathy. Annals of the New York Academy of Sciences 2007;1100:199-
206.  
[2] Siemianowicz K, Gminski J, Telega A, Wójcik A, Posielezna B, Grabowska-Bochenek R, 
Francuz T. Blood antioxidant parameters in patients with diabetic retinopathy. 
International Journal of Molecular Medicine 2004;14:433-437. 
[3] Parikh A, Fantus IG. Screening and management of diabetic microvascular 
complications in older adults. Geriatrics and Aging 2004;7:22-30.  
[4] Kurtul N, Bakan E, Aksoy H, Baykal O. Leucocyte lipid peroxidation, superoxide 
dismutase and catalase activities of type 2 diabetic patients with retinopathy. Acta 
Medica (Hradec Králowé) 2005;48(1):35-38. 
[5] Bosco Adriana, Lerário Antonio Carlos, Soriano Danilo, Santos Rosa Ferreira dos, 
Massote Píndaro, Galvão Daniela et al . Retinopatia diabética. Arq Bras Endocrinol 
Metab  [serial on the Internet]. 2005  Apr [cited 2008  Aug  22] ;  49(2): 217-227. 
Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-
27302005000200007&lng=en. doi: 10.1590/S0004-27302005000200007. 
[6] Anderson JW. Metabolic abnormalities contributing to diabetic complications. I. Glucose 
metabolism in insulin-insensitive pathways. The American Journal of Clinical 
Nutrition 1975; 28:273-280.  
[7] Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a 
therapeutic strategy in diabetes. Diabetes 2004;53 Suppl 1:S110-S118. 
[8] Mabley JG, Soriano FG. Role of nitrosative stress and poly(ADP-ribose) polymerase 
activation in diabetic vascular dysfunction. Current Vascular Pharmacology 
2005;3:247-252.  
[9] Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Third Edition. 
Oxford: Oxford University Press, 1999:23;106 - 7.  
[10] Palmieri B, Sblendorio V. Oxidative stress detection: what for? Part I. European Review 
for Medical & Pharmacological Sciences 2006;10:291-317.  
[11] Campos EBP, Yoshida WB. O papel dos radicais livres na fisiopatologia da isquemia e 
reperfusão em retalhos cutâneos: modelos experimentais e estratégias de 
tratamento. Jornal Vascular Brasileiro 2004;3(4):357-366.  
www.intechopen.com
 
Diabetic Retinopathy 
 
65 
[12] De La Cruz JP, Gonzalez-Correa JA, Guerrero A, De la Cuesta FS, et al. Pharmacological 
approach to diabetic retinopathy. Diabetes/metabolism research and reviews 
2004;20:91-113.  
[13] Gupta MM, Chari S, Gupta MM, Chari S. Lipid peroxidation and antioxidant status in 
patients with diabetic retinopathy. Indian Journal of Physiology and Pharmacology 
2005;49:187-92. 
[14] Altomare E, Grattagliano I, Vendemaile G, Micelli-Ferrari T, Signorile A, Cardia L. 
Oxidative protein damage in human diabetic eye: evidence of a retinal 
participation. European Journal of Clinical Investigation 1997; 27:141-147.  
[15] McCarty MF. Nitric oxide deficiency, leucocyte activation, and resultant ischemia are 
crucial to the pathogenesis of diebtic retinopathy/neuropathy – preventive 
potential of antioxidants, essential fatty acids, chromium, gikgkolides, and 
pentoxifylline. Medical Hypotheses 1998;50:435-449.  
[16] Kowluru RA, Kennedy A. Therapeutic potential of anti-oxidants and diabetic 
retinopathy. Expert Opinion on Investigational Drugs 2001;10:1665-76.  
[17] Caldwell RB, Bartoli M, Behzadian MA, El Remessy AE, Al Shabrawey M, Platt DH, et 
al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative 
stress. Current drug targets 2005;6:511-24.  
[18] Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion 
to retinal endothelial cells through vascular endothelial growth factor-induced 
ICAM-1 expression: inhibitory effects of antioxidants. Journal of Leukocyte Biology 
2004;75:1062-9. 
[19] Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó É, Szabó C. The role of poly(ADP-
ribose) polymerase activation in the development of myocardial and endothelial 
dysfunction in diabetes. Diabetes 2002;51:514-521.  
[20] Szabó C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virág L, et al. Part I: 
Pathogenetic role of peroxynitrite in he development of diabetes and diabetic 
vascular complications: studies with FP15, a novel potent peroxynitrite 
decomposition catalyst. Molecular Medicine 2002;8(10):571-580.  
[21] Ceriello A. New insights on oxidative stress and diabetic complications may lead to a 
“causal” antioxidant therapy. Diabetes Care 2003;26(5):1589-1596.  
[22] Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on 
antioxidant and health effects ih humans. Am. J. Clin. Nutr. 1999;69:1086-1107.  
[23] Soro-Paavonen A, Forbes JM. Novel therapeutics for diabetic micro- and macrovascular 
complications. Current Medicinal Chemistry 2006;13:1777-88.  
[24] Juhl B. Vitamin C treatment reduces transcapillary escape rate of albumin in type 1 
diabetes. European Journal of Internal Medicine 2004;15:428-35.  
[25] Root-Bernstein R, Busik JV, Henry DN. Are diabetic neuropathy, retinopathy and 
nephropathy caused by hyperglicemic exclusion of dehydroascorbate uptake by 
glucose transporters? J. Theor. Biol. 2002;216:345-359. 
[26] Rema M, Mohan V, Bhaskar A, Shanmugasundaram KR. Does oxidant stress play a role 
in diabetic retinopathy? Indian J. Ophthalmol. 1995;43:17-21.  
[27] Vinson J, Hsu C, Possanza C, Drack A, Pane D, Davis R, et al. Lipid peroxidation and 
diabetic complications: effect of antioxidant vitamins C and E. Advances in 
experimental medicine and biology 1944;366:430-2.  
www.intechopen.com
 
Diabetic Retinopathy 
 
66
[28] Millen AE, Gruber M, Klein R, Klein BEK, Palta M, Mares JA. Relations of serum 
ascorbic acid and ǂ-tocopherol to diabetic retinopathy in the Third National Health 
and Nutrition Examination Survey. American Journal of Epidemiology 
2003;158:225-233. 
[29] Campos S. Medicina Biomolecular e Radicais Livres. São Paulo, Francolor Artes 
Gráficas e Editora Ltda., 1996:Vol 1:137-143.  
[30] Kowluru RA, Ho Y-S. Role of mitochondrial superoxide dismutase in the development 
of diabetic retinopathy. Investigative Ophthalmology and Visual Science 
2006;47:1594-1599. 
[31] Wikipedia The Free Encyclopedia [text on the Internet]. Los Angeles, The Wikimedia 
Foundation, Inc.; 2008 [cited 2009 Jan 12]. Disponível em: 
http://en.wikipedia.org/wiki/Bcl-2.  
[32] McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for 
erythrocuprein (hemocuprein). J. Biol. Chem. 1969;244(22):6049-6055. 
[33] Kresge N, Simoni RD, Hill RL. Forty years of superoxide dismutase research: the work 
of Irwin Fridovich. J. Biol. Chem. 2006;281(22);issue of June 2:p.e17-e19. 
[34] Balasubramanyam M, Rema M, Premanand C. Biochemical and molecular mechanisms 
of diabetic retinopathy. Current Science 2002;83:1506-14.  
www.intechopen.com
Diabetic Retinopathy
Edited by Dr. Mohammad Shamsul Ola
ISBN 978-953-51-0044-7
Hard cover, 356 pages
Publisher InTech
Published online 24, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The aim of this book is to provide a comprehensive overview of current concepts in pathogenesis, diagnosis
and treatments of diabetic retinopathy. It provides a collection of topics written by excellent authors, covering
discussions on advances in understanding of pathophysiology, immunological factors and emerging concepts,
relating to clinical aspects and treatment strategies. The contents of the book will not only provide a resource
for our knowledge but also improve diagnosis and treatment options for those patients who suffer vision loss
due to diabetic retinopathy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Carlos Ce ́sar Lopes De Jesus (2012). Diabetic Retinopathy, Diabetic Retinopathy, Dr. Mohammad Shamsul
Ola (Ed.), ISBN: 978-953-51-0044-7, InTech, Available from: http://www.intechopen.com/books/diabetic-
retinopathy/diabetic-retinopathy
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
